

S5 Table. Risk factors for mortality in patients with stage IV adenocarcinoma assessed by Cox proportional hazards model

	Univariate analysis			Multivariable analysis		
	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Age	1.023	1.013-1.022	< 0.001	1.014	1.000-1.028	0.053
Male sex	1.439	1.143-1.812	0.002	0.853	0.522-1.394	0.525
Ever-smoker	1.405	1.122-1.760	0.003	1.756	1.080-2.855	0.023
BMI	0.995	0.980-1.010	0.536			
Performance status						
0-1 (ref)	1.000			1.000		
2-4	2.327	1.630-3.323	< 0.001	1.675	1.082-2.594	0.021
EGFR	0.651	0.508-0.834	< 0.001	0.977	0.552-1.732	0.937
ALK	0.442	0.246-0.792	0.006	0.416	0.150-1.155	0.092
Treatment						
BSC (ref)	1.000			1.000		
EGFR inhibitor	0.504	0.371-0.685	< 0.001	0.468	0.262-0.835	0.010
ALK inhibitor	0.477	0.232-0.984	0.045	1.629	0.448-5.928	0.459
Chemotherapy	0.800	0.589-1.087	0.154	0.711	0.471-1.071	0.103

ALK, anaplastic lymphoma kinase; BMI, body mass index; BSC, best supportive care; CI, confidence interval; EGFR, epidermal growth factor receptor.